

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

NORMAL SINUS RHYTHM **ECG**

MAMOGRAPHY (BOTH BREASTS)

MAMOGRAPHY BOTH BREASTS **BREAST USG:-**

SONOGRAM OF BREAST REVEALS :-

Normal fibro-glandular & parenchymal appearance.

Normal axillary tail region. Nipple shadow is normal.

No evidence of enlarged axillary L.N. Retromamary region is normal.

IMPRESSION: - NORMAL SONOGRAPHIC APPEARANCE OF BILATERAL

BREASTS.

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY NOT SIGNIFICANT RELEVANT PERSONAL HISTORY **NOT SIGNIFICANT**

MENSTRUAL HISTORY (FOR FEMALES) **REGULAR** LMP (FOR FEMALES) 09/03/2024 OBSTETRIC HISTORY (FOR FEMALES) G2,P2,A0,L2 12 YEARS LCB (FOR FEMALES) **HYPERTENSION** RELEVANT FAMILY HISTORY

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kapadia

Dr.Priyank Kapadia **Physician**





Page 1 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09 REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

NOT SIGNIFICANT OCCUPATIONAL HISTORY HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.64 mts WEIGHT IN KGS. 66.7 Kgs

BMI 25 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL OVERWEIGHT**

GENERAL APPEARANCE / NUTRITIONAL

STATUS AVERAGE BUILT / SKELETAL FRAMEWORK NORMAL FACIAL APPEARANCE **NORMAL** SKIN **NORMAL** UPPER LIMB LOWER LIMB **NORMAL** NORMAL **NECK**

NOT ENLARGED OR TENDER NECK LYMPHATICS / SALIVARY GLANDS

NOT ENLARGED THYROID GLAND

TEMPERATURE NORMAL PULSE 64/MIN RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kapadia

Dr.Priyank Kapadia **Physician**





Page 2 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09 REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

BP 100/66 MM HG mm/Hg

(SITTING) **NORMAL PERICARDIUM** APEX BEAT **NORMAL**

HEART SOUNDS S1, S2 HEARD NORMALLY

ABSENT MURMURS

RESPIRATORY SYSTEM

NORMAL SIZE AND SHAPE OF CHEST SYMMETRICAL MOVEMENTS OF CHEST BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT**

PER ABDOMEN

APPEARANCE NORMAL LIVER **NOT PALPABLE SPLEEN NOT PALPABLE**

CENTRAL NERVOUS SYSTEM

NORMAL HIGHER FUNCTIONS CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS **NORMAL** SENSORY SYSTEM **NORMAL NORMAL** MOTOR SYSTEM **REFLEXES NORMAL**

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kapadia

Dr.Priyank Kapadia **Physician**





Page 3 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

| |PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

ABHA NO :

102,02,011110015

DRAWN :

RECEIVED : 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITHOUT 6/9

GLASSES

DISTANT VISION LEFT EYE WITHOUT 6/9

GLASSES

NEAR VISION RIGHT EYE WITHOUT GLASSES N/10
NEAR VISION LEFT EYE WITHOUT GLASSES N/10
COLOUR VISION NORMAL

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS WITHIN NORMAL LIMITS

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS NONE

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY: - DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY: - DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST: - DR. SAHIL N SHAH (M.D.RADIOLOGY)

Dr.Sahil .N.Shah Consultant Radiologist Dr.Priyank Kapadia Physician

P. V. Kapadia



Page 4 Of 24

View Details

View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

| |PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

ABHA NO :

DRAWN ·

RECEIVED : 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

Test Report Status <u>Final</u> Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

TMT OR ECHO

CLINICAL PROFILE

2D ECHO:-

- 1) NORMAL CHAMBERS AND VALVES.
- 2) GOOD LV SYSTOLIC FUNCTION. LVEF 65%. NO RWMA AT REST.
- 3) NO MR, AR, TR.
- 4) NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.
- 7) IAS/IVS INTACT.

Interpretation(s)

MEDICAL

Dr.Sahil .N.Shah

Dr Brivank Kan

P. V. Kapadia

Dr.Priyank Kapadia Physician





Page 5 Of 24

View Details

View Report



Consultant Radiologist

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SNEHF021082321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 23/03/2024 09:41:09

DELHI REPORTED :29/03/2024 16:42:43 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results **Biological Reference Interval** Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP AI	BOVE 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.0	12.0 - 15.0	g/dL
METHOD: PHOTOMETRIC MEASUREMENT	4 27	2.0 4.0	mail / l
RED BLOOD CELL (RBC) COUNT METHOD: COULTER PRINCIPLE	4.27	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT	5.50	4.0 - 10.0	thou/µL
METHOD : COULTER PRINCIPLE			
PLATELET COUNT	170	150 - 410	thou/μL
METHOD: COULTER PRINCIPLE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	37.7	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV)	88.3	83.0 - 101.0	fL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	00.0	05.0 101.0	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.1	27.0 - 32.0	pg
METHOD : CALCULATED	21.0	21 5 24 5	g/dL
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.8	31.5 - 34.5	g/uL
METHOD : CALCULATED			
RED CELL DISTRIBUTION WIDTH (RDW)	14.0	11.6 - 14.0	%
MENTZER INDEX	20.7		
METHOD : CALCULATED PARAMETER	_3.,		
MEAN PLATELET VOLUME (MPV)	12.6 High	6.8 - 10.9	fL
METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	56	40 - 80	%
METHOD : OPTICAL IMPEDENCE & MICROCSOPY	50	1 0 - 00	70
LYMPHOCYTES	33	20 - 40	%

Dr.Miral Gajera Consultant Pathologist





Page 6 Of 24





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India

Tel: 079-48912999,079-48913999,079-48914999 Email: customer care. ahmed abad@agilus. in

METHOD: OPTICAL IMPEDENCE & MICROCSOPY





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : SNEHF021082321 F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: DELHI

ABHA NO **NEW DELHI 110030** 8800465156

RECEIVED: 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

	į	į	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
MONOCYTES	7	2.0 - 10.0	%
METHOD: OPTICAL IMPEDENCE & MICROCSOPY			
EOSINOPHILS	3	1.0 - 6.0	%
METHOD: OPTICAL IMPEDENCE & MICROCSOPY			
BASOPHILS	1	0 - 1	%
METHOD : IMPEDANCE			
ABSOLUTE NEUTROPHIL COUNT	3.08	2.0 - 7.0	thou/µL
METHOD: CALCULATED			
ABSOLUTE LYMPHOCYTE COUNT	1.82	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.39	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.17	0.02 - 0.50	thou/µL
METHOD: CALCULATED			
ABSOLUTE BASOPHIL COUNT	0.06	0.02 - 0.10	thou/µL
METHOD: CALCULATED			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.7		
METHOD: CALCULATED PARAMETER			

MORPHOLOGY

PLATELETS

REMARKS

NORMOCYTIC NORMOCHROMIC **RBC**

METHOD: MICROSCOPIC EXAMINATION

NORMAL MORPHOLOGY **WBC**

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED.

ADEQUATE

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Dr.Miral Gajera **Consultant Pathologist**





Page 7 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





Female

PATIENT NAME: SNEHA JHA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

:41 Years

REPORTED : 29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist



Page 8 Of 24





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





mm at 1 hr

REF. DOCTOR: SELF PATIENT NAME: SNEHA JHA

CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09 REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval Final** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R 20 0 - 20

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic: < 5.7 HBA1C 5.0 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0

(ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 96.8 < 116.0 mg/dL

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an ondition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Earloger infection, agring. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr.Miral Gaiera Consultant Pathologist



Page 9 Of 24



Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera **Consultant Pathologist**



Page 10 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT II

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156 PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO : DRAWN :

RECEIVED : 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

Test Report Status <u>Final</u> Results Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist



Page 11 Of 24

View Details

View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

METHOD: HEXOKINASE

METHOD: HEXOKINASE

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

RECEIVED: 23/03/2024 09:41:09

REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

ABHA NO

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

81

74 - 99

mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

101

70 - 140

mg/dL

LIPID PROFILE WITH CALCULATED LDL, SERUM

mg/dL CHOLESTEROL, TOTAL 147 Desirable: < 200

BorderlineHigh: 200 - 239

High: > or = 240

51 Desirable: < 150 mg/dL TRIGLYCERIDES

BorderlineHigh: 150 - 199

High: 200 - 499

Very High: > or = 500

METHOD: ENZYMATIC, COLORIMETRIC

METHOD: ENZYMATIC, COLORIMETRIC

HDL CHOLESTEROL 48 mg/dL < 40 Low

> or = 60 High

CHOLESTEROL LDL 89 Adult levels: mg/dL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189

Very high: = 190

99 NON HDL CHOLESTEROL Desirable: Less than 130 mg/dL

10.2

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

< or = 30

mg/dL

Dr.Miral Gaiera Consultant Pathologist



Page 12 Of 24



Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India

Tel: 079-48912999,079-48913999,079-48914999 Email: customercare.ahmedabad@agilus.in

VERY LOW DENSITY LIPOPROTEIN





PATIENT NAME: SNEHA JHA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : SNEHF021082321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 23/03/2024 09:41:09 DELHI ABHA NO REPORTED :29/03/2024 16:42:43 **NEW DELHI 110030** 8800465156

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
CHOL (HDL DATE)		24 1	22.44
CHOL/HDL RATIO		3.1 Low	3.3 - 4.4
LDL/HDL RATIO		1.9	0.5 - 3.0 Desirable/Low Risk
			3.1 - 6.0 Borderline/Moderate
			Risk
			>6.0 Hiah Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	f premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td>$\langle OR = 60 \rangle$</td><td>> 30</td><td>>60</td></or>	$\langle OR = 60 \rangle$	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

Dr.Miral Gajera Consultant Pathologist





Page 13 Of 24

liew Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015





 CODE/NAME & ADDRESS : C000138364
 ACCESSION NO : 0321XC001793
 AGE/SEX :41 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SNEHF021082321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/03/2024 09:41:09

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
DY IDUDY TOTAL	0.22	Hata 4.2	
BILIRUBIN, TOTAL	0.32	Upto 1.2	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO COLORIMETRIC	0.17	Upto 0.2	mg/dL
BILIRUBIN, INDIRECT	0.15	0.00 - 1.00	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.0	6.4 - 8.3	g/dL
ALBUMIN	4.6	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			-
GLOBULIN	2.4	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.9	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	15	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	14	0 - 33	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	87	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	7	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD: UV ASSAY METHOD	266 High	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	6	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD: JAFFE ALKALINE PICRATE	0.57 Low	0.60 - 1.10	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	10.53	5.0 - 15.0	

Dr.Miral Gajera Consultant Pathologist






Page 14 Of 24

View Details



PERFORMED AT :

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India







CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

URIC ACID, SERUM

URIC ACID 4.2 2.4 - 5.7mg/dL

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.0 6.4 - 8.3g/dL

METHOD: COLORIMETRIC

ALBUMIN, SERUM

g/dL 4.6 3.5 - 5.2ALBUMIN

METHOD: BROMOCRESOL GREEN

GLOBULIN

GLOBULIN 2.4 2.0 - 4.1g/dL

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM 139.7 136-145 mmol/L 3.50-5.10 mmol/L POTASSIUM, SERUM 4.62 CHLORIDE, SERUM 108.7 High 98 - 107 mmol/L

Interpretation(s)

Sodium Potassium Chloride

Dr.Miral Gajera **Consultant Pathologist**



Page 15 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO : 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED: 29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval Final** Units

Decreased in: CCF. cirrhosis. Decreased in: Low potassium Decreased in: Vomiting, diarrhea. vomiting, diarrhea, excessive intake, prolonged vomiting or diarrhea, renal failure combined with salt sweating, salt-losing RTA types I and II, deprivation, over-treatment with nephropathy, adrenal insufficiency, hyperaldosteronism, Cushing's diuretics, chronic respiratory acidosis, nephrotic syndrome, water syndrome, osmotic diuresis (e.g. diabetic ketoacidosis, excessive intoxication, SIADH. Drugs: hyperglycemia), alkalosis, familial sweating, SIADH, salt-losing thiazides, diuretics, ACE inhibitors, periodic paralysis,trauma nephropathy, porphyria, expansion of chlorpropamide,carbamazepine,anti (transient). Drugs: Adrenergic agents, extracellular fluid volume, depressants (SSRI), antipsychotics. adrenalinsufficiency, diuretics. hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics. Increased in: Dehydration Increased in: Massive hemolysis, Increased in: Renal failure, nephrotic (excessivesweating, severe severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, vomiting or diarrhea).diabetes acidosis, dehydration, renal failure. overtreatment with Addison's disease, RTA type IV, mellitus, diabetesinsipidus, saline, hyperparathyroidism, diabetes hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory water intake. Drugs: steroids. paralysis. Drugs: potassium salts, licorice.oral contraceptives. potassium- sparing diuretics.NSAIDs. alkalosis.hyperadrenocorticism. beta-blockers, ACE inhibitors, high-Drugs: acetazolamide.androgens. dose trimethoprim-sulfamethoxazole hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences:Test is helpful in hyperproteinemi, if sodium analysis delayed separation of serum, assessing normal and increased anion involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium drawing, and prolonged tourniquet distinguishing hypercalcemia due to falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum mg/dL increase in blood glucose. may cause spurious. Plasma potassium chloride) from that due to malignancy levels are normal. (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic

Dr.Miral Gaiera Consultant Pathologist





Page 16 Of 24



Agilus Diagnostics Ltd. Grand Malī, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID:

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED: 29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval Final** Units

ABHA NO

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gajera

Consultant Pathologist



Page 17 Of 24



Agilus Diagnostics Ltd. Grand Malī, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Email: customercare.ahmedabad@agilus.in



Gujrat, India Tel: 079-48912999,079-48913999,079-48914999



CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED :29/03/2024 16:42:43

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR Yellow **APPEARANCE** Clear

CHEMICAL EXAMINATION, URINE

PH	5.0	4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY SPECIFIC GRAVITY <=1.005 1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED **PROTEIN**

METHOD: REFLECTANCE SPECTROPHOTOMETRY **GLUCOSE** NOT DETECTED **NEGATIVE**

METHOD: REFLECTANCE SPECTROPHOTOMETRY **NOT DETECTED** NOT DETECTED **KETONES**

METHOD: REFLECTANCE SPECTROPHOTOMETRY

DETECTED (TRACE) NEGATIVE BLOOD METHOD: REFLECTANCE SPECTROPHOTOMETRY

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY UROBILINOGEN **NORMAL NORMAL**

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NITRITE NOT DETECTED NOT DETECTED METHOD: REFLECTANCE SPECTROPHOTOMETRY

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

METHOD: MICROSCOPIC EXAMINATION

METHOD: REFLECTANCE SPECTROPHOTOMETRY

RED BLOOD CELLS 0 - 1NOT DETECTED /HPF METHOD: MICROSCOPIC EXAMINATION

/HPF PUS CELL (WBC'S) NOT DETECTED 0-5

EPITHELIAL CELLS 8-10 0-5 /HPF

Dr.Miral Gaiera Consultant Pathologist



Page 18 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





PATIENT NAME: SNEHA JHA

REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID: SNEHF021082321

REF. DOCTOR: SELF

AGE/SEX: 41 Years Female
DRAWN:

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI
NEW DELHI 110030

CLIENT PATIENT ID: RECEIVED : 23/03/2024 09:41:09
REPORTED : 29/03/2024 16:42:43

Test Report Status <u>Final</u> Results Biological Reference Interval Units

METHOD: MICROSCOPIC EXAMINATION

8800465156

CASTS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

REMARKS

MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON

CENTRIFUGED URINARY SEDIMENT.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary		
	tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either		
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by		
	genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or		
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,		
	interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal		
	diseases		

Dr.Miral Gajera Consultant Pathologist



Page 19 Of 24

View Details





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : SNEHF021082321 DRAWN

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 23/03/2024 09:41:09 DELHI REPORTED :29/03/2024 16:42:43 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results **Biological Reference Interval** Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist





Page 20 Of 24



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





 CODE/NAME & ADDRESS : C000138364
 ACCESSION NO : 0321XC001793
 AGE/SEX :41 Years
 Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

i PATIENT ID : SNEHF021082321

FAILNI ID SNEHFUZIU8Z.

CLIENT PATIENT ID: ABHA NO : DRAWN :

RECEIVED : 23/03/2024 09:41:09 REPORTED : 29/03/2024 16:42:43

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE TWO UNSTAINED CERVICAL SMEARS RECEIVED

REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY SMEARS ARE SATISFACTORY FOR EVALUATION.

MICROSCOPY

SMEARS SHOW PREDOMINANTLY INTERMEDIATE AND PARABASAL
SQUAMOUS CELLS AGAINST BACKGROUND OF MIXED INFLAMMATORY

CELLS. ENDOCERVICAL CELLS ARE SEEN ON SMEAR. NO EVIDENCE OF

DYSPLASIA OR MALIGNANT CELLS SEEN.

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

PAP SMEAR IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE RESULTS SHOULD BE INTERPRETED WITH CAUTION.

Dr.Miral Gajera Consultant Pathologist





Page 21 Of 24

View Details

View Report



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

<u>Final</u>

DELHI

NEW DELHI 110030

Test Report Status

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

RECEIVED: 23/03/2024 09:41:09 REPORTED: 29/03/2024 16:42:43

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

ng/dL T3 86.64 Non-Pregnant Women

Results

80.0 - 200.0 Pregnant Women

1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0

METHOD: ECLIA

T4 8.06 Non-Pregnant Women μg/dL

> 5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD : ECLIA

TSH (ULTRASENSITIVE) 1.280 Non Pregnant Women µIU/mL

0.27 - 4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

Dr.Miral Gaiera Consultant Pathologist



Page 22 Of 24



Agilus Diagnostics Ltd. Grand Malī, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





Female

PATIENT NAME: SNEHA JHA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321XC001793 AGE/SEX

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

:41 Years

REPORTED :29/03/2024 16:42:43

Test Report Status Results Biological Reference Interval Units <u>Final</u>

active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr.Miral Gajera **Consultant Pathologist**



Page 23 Of 24





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321XC001793 AGE/SEX :41 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

PATIENT ID : SNEHF021082321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 23/03/2024 09:41:09

REPORTED :29/03/2024 16:42:43

Test Report Status Results Biological Reference Interval Units **Final**

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gaiera Consultant Pathologist



Page 24 Of 24



Agilus Diagnostics Ltd. Grand Malı, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India

